Kintara Therapeutics, Inc.

NasdaqCM:KTRA Stock Report

Market Cap: US$12.8m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Kintara Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Kintara Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Seeking Alpha • Oct 19

Kintara soars 66% on pausing breast cancer study, to use cash for brain cancer trial

Kintara Therapeutics (NASDAQ:KTRA) said it paused its REM-001 program in cutaneous metastatic breast cancer (CMBC) to save cash. The money will be used to fund an ongoing international registrational study of VAL-083 to treat a type of brain cancer called glioblastoma (GBM), the company said in a statement on Wednesday. Kintara President and CEO Robert Hoffman expects results from the GBM AGILE study of VAL-083 at the end of 2023. By pausing the REM-001 program, Kintara expects to save ~$3M through 2023. "We will continue to explore ways to restart REM-001, including use of grants from applications currently under review to support the funding of the planned 15-patient CMBC study. Although this was a difficult decision, we believe saving approximately $3.0 million through calendar year 2023 is prudent given the current capital market conditions," said Hoffman. KTRA +65.73% to $0.17 premarket Oct. 19
Seeking Alpha • Sep 27

Kintara Therapeutics GAAP EPS of -$0.52

Kintara Therapeutics press release (NASDAQ:KTRA): FY GAAP EPS of -$0.52. At June 30, 2022, Kintara had cash and cash equivalents of approximately $11.8 million.
Seeking Alpha • Aug 03

Kintara Therapeutics rallies after $20M stock purchase deal with Lincoln Park Capital Fund

Kintara Therapeutics (NASDAQ:KTRA) stated Wednesday it has signed a direct equity purchase agreement for up to $20M investment with a Chicago-based institutional investor- Lincoln Park Capital Fund. Under the deal, Kintara will have the right, but not the obligation, to sell to LPC up to $20M of its shares over the period of 3-year agreement term. The company expects this commitment from LPC will provide financial flexibility and is aligned with Kintara's long-term strategy for value creation. KTRA shares jump 64% in pre-market, Wednesday.  Kintara said it intends to use net proceeds from the sale of its common stock to LPC for working capital and general corporate purposes, including development expenses for VAL-083 and REM-001.
Analysis Article • Apr 12

Kintara Therapeutics (NASDAQ:KTRA) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kintara Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:KTRA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024N/A-9-7-7N/A
3/31/2024N/A-10-7-7N/A
12/31/2023N/A-11-7-7N/A
9/30/2023N/A-13-7-7N/A
6/30/2023N/A-15-12-12N/A
3/31/2023N/A-17-16-15N/A
12/31/2022N/A-19-19-19N/A
9/30/2022N/A-22-22-22N/A
6/30/2022N/A-25-20-20N/A
3/31/2022N/A-26-20-20N/A
12/31/2021N/A-28-20-19N/A
9/30/2021N/A-27-20-20N/A
6/30/2021N/A-42-19-19N/A
3/31/2021N/A-39-17-17N/A
12/31/2020N/A-34-13-13N/A
9/30/2020N/A-30-10-10N/A
6/30/2020N/A-9-8-8N/A
3/31/2020N/A-8-7-7N/A
12/31/2019N/A-8-7-7N/A
9/30/2019N/A-8-7-7N/A
6/30/2019N/A-8-6-6N/A
3/31/2019N/A-8-7-7N/A
12/31/2018N/A-9-8-8N/A
9/30/2018N/A-11-10-10N/A
6/30/2018N/A-11-10-10N/A
3/31/2018N/A-12N/A-11N/A
12/31/2017N/A-11N/A-9N/A
9/30/2017N/A-9N/A-9N/A
6/30/2017N/A-9N/A-8N/A
3/31/2017N/A-10N/A-6N/A
12/31/2016N/A-9N/A-6N/A
9/30/2016N/A-10N/A-5N/A
6/30/2016N/A-9N/A-5N/A
3/31/2016N/A-6N/A-4N/A
12/31/2015N/A-6N/A-4N/A
9/30/2015N/A-4N/A-4N/A
6/30/2015N/A-4N/A-4N/A
3/31/2015N/A-1N/A-4N/A
12/31/2014N/A-2N/A-4N/A
9/30/2014N/A-2N/A-4N/A
6/30/2014N/A6N/A-4N/A
3/31/2014N/A-4N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if KTRA's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if KTRA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if KTRA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if KTRA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if KTRA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KTRA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/17 07:21
End of Day Share Price 2024/10/17 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kintara Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group